- With the approval of amendment X, all patients in cohort 4 will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine followed by the infusion of autologous TIL and then begin high-dose aldesleukin (720,000 IU/kg IV every 8 hours for up to 12 doses).